Viela is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Our team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space and our research focuses on well-established critical biological pathways shared across multiple indications. We believe that our approach – which targets the underlying molecular pathogenesis of the disease – enables us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications for each of our product candidates.
We recently announced that the U.S. FDA approved UPLIZNA® (inebilizumab-cdon) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquarporin-4 (AQP4) antibody positive. In parallel to initiating the commercialization of UPLIZNA®, we continue to expand on the opportunity by advancing multiple clinical trials with inebilizumab in various indications including myasthenia gravis, IgG4-related disease, and kidney transplant rejection. Our pipeline also includes novel candidates, VIB4920 and VIB7734, which we are pursuing for the treatment of a variety of serious and debilitating autoimmune diseases.